ArticleEuropean radiology experimental2026
TACE plus donafenib and immune checkpoint inhibitors for intermediate HCC (CHANCE2410 study): a propensity score matching analysis.
Article in European radiology experimental, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
Abstract
objectiveTo compare the efficacy and safety of transarterial chemoembolization (TACE) plus donafenib and immune checkpoint inhibitors (ICIs) (combination therapy) versus TACE monotherapy for intermediate hepatocellular carcinoma (HCC). MATERIALS AND
methodsThis nationwide, multicenter, retrospective cohort study included intermediate HCC patients receiving either combination therapy or TACE monotherapy between January 2021 and May 2024. The primary outcome was progression-free survival (PFS). The secondary outcomes included overall survival (OS) rate, objective response rate (ORR), and safety. Propensity score matching (PSM) analysis was employed to minimize bias. The Cox proportional-hazards regression model was used to analyze factors affecting PFS and OS.
resultsOf 364 patients enrolled, 192 received combination therapy and 172 received TACE monotherapy with a baseline up-to-seven distribution (≤ 7 = 30%, > 7 = 70%). After PSM, 127 pairs were analyzed. Median PFS was significantly longer for the combination therapy than for TACE monotherapy (19.6 months [95% confidence interval, CI 14.9‒24.4] versus 15.3 months [95% CI 12.8-17.8], hazard ratio 0.647 [95% CI 0.464-0.903], p = 0.010). The combination therapy group showed better OS rate (94.8% versus 83.5%, 1-year OS rate; 76.4% versus 64.8%, 2-year OS rate; hazard ratio 0.542 [95% CI 0.327‒0.898], p = 0.016) and ORR (78.9% versus 62.5%, p = 0.002). Grade 3 or 4 adverse events from any cause were 12.5% in the combination group versus 5.5% in the monotherapy group. Multivariate analysis identified combination therapy as an independent prognostic factor for both longer PFS and OS.
conclusionTACE plus donafenib and ICIs offer superior PFS and OS, supporting its use as an alternative option for intermediate HCC. RELEVANCE STATEMENT: The study highlights the efficacy of the combination therapy of TACE plus donafenib and ICIs in the real world. It has the potential to act as an alternative for the treatment of intermediate HCC with an acceptable safety profile. KEY POINTS: Large real-world studies evaluating the combination therapy of TACE plus donafenib and ICIs for intermediate HCC patients are scarce. The combination therapy significantly improved PFS, OS, and ORR compared to TACE monotherapy, with a manageable safety profile. TACE plus donafenib and ICIs could serve as an alternative option for intermediate HCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.